Emmanuel Feroldi
About
Emmanuel Feroldi is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Epidemiology.
According to data from OpenAlex, Emmanuel Feroldi has authored 25 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 16 papers in Public Health, Environmental and Occupational Health and 9 papers in Epidemiology. Recurrent topics in Emmanuel Feroldi's work include Mosquito-borne diseases and control (16 papers), Viral Infections and Vectors (15 papers) and Viral Infections and Outbreaks Research (12 papers). Emmanuel Feroldi is often cited by papers focused on Mosquito-borne diseases and control (16 papers), Viral Infections and Vectors (15 papers) and Viral Infections and Outbreaks Research (12 papers). Emmanuel Feroldi collaborates with scholars based in France, United States and Thailand. Emmanuel Feroldi's co-authors include Alain Bouckenooghe, Mark Boaz, Claude Méric, Chitsanu Pancharoen, Jean Lang, Karen McCarthy, Sophia Gailhardou, Emilia Jordanov, Kulkanya Chokephaibulkit and María Rosario Capeding and has published in prestigious journals such as The Journal of Infectious Diseases, Vaccine and The Pediatric Infectious Disease Journal.
In The Last Decade
Emmanuel Feroldi
24 papers receiving 482 citations
Peers
Emmanuel Feroldi
Nivedita Gupta India
Jayantha Liyanage United States
Regina Rabinovich Spain
Zsófia Mészner Hungary
Jason Martin United States
Alix Collard Belgium
Shailesh Dewasthaly Austria
Lee-Jah Chang United States
Chule Thisyakorn Thailand
Maria Theresa Alera United States
Citations per year, relative to Emmanuel Feroldi Emmanuel Feroldi (= 1×)
peers
Nivedita Gupta
Countries citing papers authored by Emmanuel Feroldi
Since
Specialization
Citations
This map shows the geographic impact of Emmanuel Feroldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuel Feroldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuel Feroldi more than expected).
Fields of papers citing papers by Emmanuel Feroldi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Emmanuel Feroldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuel Feroldi. The network helps show where Emmanuel Feroldi may publish in the future.
Co-authorship network of co-authors of Emmanuel Feroldi
This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuel Feroldi. A scholar is included among the top collaborators of Emmanuel Feroldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuel Feroldi. Emmanuel Feroldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Carré, Christophe, et al.. (2024). Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial. EBioMedicine. 108. 105332–105332.
2.
Ataman‐Önal, Yasemin, Benjamin G. Chousterman, Emmanuel Feroldi, et al.. (2020). Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28–29, 2017, Marcy l’Etoile, France. Vaccine. 38(51). 8055–8063.
3.
Martinón‐Torres, Federico, et al.. (2018). Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers. The Pediatric Infectious Disease Journal. 38(3). 317–322.
4.
Bouckenooghe, Alain, Fabrice Bailleux, & Emmanuel Feroldi. (2018). Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine. Human Vaccines & Immunotherapeutics. 15(1). 72–79.
5.
Prymula, Roman, et al.. (2018). Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic. The Pediatric Infectious Disease Journal. 37(8). 823–830.
6.
Chokephaibulkit, Kulkanya, Chukiat Sirivichayakul, Usa Thisyakorn, et al.. (2016). Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children. Vaccine. 34(46). 5664–5669.
7.
Kosalaraksa, Pope, Veerachai Watanaveeradej, Chitsanu Pancharoen, et al.. (2016). Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization. The Pediatric Infectious Disease Journal. 36(4). e108–e113.
8.
Vesikari, Timo, Sven‐Arne Silfverdal, Emilia Jordanov, & Emmanuel Feroldi. (2016). A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule. The Pediatric Infectious Disease Journal. 36(1). 87–93.
9.
Feroldi, Emmanuel, Mark Boaz, Sutee Yoksan, et al.. (2016). Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization Five Years following JE-CV Immunization. The Journal of Infectious Diseases. 215(2). jiw533–jiw533.
10.
Feroldi, Emmanuel, Chitsanu Pancharoen, Pope Kosalaraksa, et al.. (2014). Primary Immunization of Infants and Toddlers in Thailand with Japanese Encephalitis Chimeric Virus Vaccine in Comparison with SA14-14-2. The Pediatric Infectious Disease Journal. 33(6). 643–649.
11.
Huang, Li‐Min, Tzou‐Yien Lin, Cheng‐Hsun Chiu, et al.. (2014). Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan. Vaccine. 32(41). 5363–5369.
12.
Bonaparte, Matthew, Emmanuel Feroldi, Claude Méric, et al.. (2014). Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India. BMC Infectious Diseases. 14(1). 156–156.
13.
Feroldi, Emmanuel, María Rosario Capeding, Mark Boaz, et al.. (2013). Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Human Vaccines & Immunotherapeutics. 9(4). 889–897.
14.
Feroldi, Emmanuel, Chitsanu Pancharoen, Pope Kosalaraksa, et al.. (2012). Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial. Human Vaccines & Immunotherapeutics. 8(7). 929–937.
15.
Torresi, Joseph, Karen McCarthy, Emmanuel Feroldi, & Claude Méric. (2010). Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine. 28(50). 7993–8000.
16.
Chokephaibulkit, Kulkanya, Chukiat Sirivichayakul, Usa Thisyakorn, et al.. (2010). Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-olds. The Pediatric Infectious Disease Journal. 29(12). 1111–1117.
17.
Nasveld, Peter, Joanne Marjason, John Aaskov, et al.. (2010). Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine. Human Vaccines. 6(11). 906–914.
18.
Nasveld, Peter, Joanne Marjason, John Aaskov, et al.. (2010). Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.. PubMed. 6(11). 906–14.
19.
Feroldi, Emmanuel, et al.. (2008). Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Transactions of the Royal Society of Tropical Medicine and Hygiene. 102(3). 294–296.
20.
Lang, Jean, et al.. (2007). Pre-exposure Purified Vero Cell Rabies Vaccine and Concomitant Routine Childhood Vaccinations: 5-year Post-vaccination Follow-up Study of an Infant Cohort in Vietnam. Journal of Tropical Pediatrics. 55(1). 26–31.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nivedita Gupta Breakdown of academic impact, for papers by Jayantha Liyanage Breakdown of academic impact, for papers by Regina Rabinovich Breakdown of academic impact, for papers by Zsófia Mészner Breakdown of academic impact, for papers by Jason Martin Breakdown of academic impact, for papers by Alix Collard Breakdown of academic impact, for papers by Shailesh Dewasthaly Breakdown of academic impact, for papers by Lee-Jah Chang Breakdown of academic impact, for papers by Chule Thisyakorn Breakdown of academic impact, for papers by Maria Theresa Alera